Skip to content

Veradermics MANE Proceeds From Notes Payable

Proceeds From Notes Payable at other companies

TRG
Targa ResourcesTRGP
$31.82B+25.1%
Jones Lang LaSalle logo
Jones Lang LaSalleJLL
$942.75M+314%
Global Payments logo
Global PaymentsGPN
$0
ACM Research logo
ACM ResearchACMR
$36.13M+112%
Jones Lang LaSalle logo
Jones Lang LaSalleJLL
$942.75M+314%
Chicago Atlantic Real Estate Finance logo
Chicago Atlantic Real Estate FinanceREFI

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$3.92B

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromNotesPayable.

The official record: Veradermics ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's proceeds from notes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veradermics 's proceeds from notes payable?
Veradermics (MANE) reported proceeds from notes payable of $0 in Q4 2025.
How has Veradermics 's proceeds from notes payable changed year-over-year?
Veradermics 's proceeds from notes payable decreased by 100.0% year-over-year, from $2.13M to $0.